 Connection
William Robinson to Dose-Response Relationship, Drug
This is a "connection" page, showing publications William Robinson has written about Dose-Response Relationship, Drug.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.109 |
|
|
|
-
Robinson WA, Miller TL, Harrold EA, Bemis LT, Brady BM, Nelson RP. The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. Melanoma Res. 2003 Jun; 13(3):231-8.
Score: 0.040
-
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
Score: 0.036
-
Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology. 1986 Sep; 172(3-5):275-82.
Score: 0.012
-
Mahmood T, Robinson WA. Effect of levamisole on human granulopoiesis in vitro. Proc Soc Exp Biol Med. 1977 Nov; 156(2):359-64.
Score: 0.007
-
McElhinney DB, Hoffman SJ, Robinson WA, Ferguson J. Effect of melatonin on human skin color. J Invest Dermatol. 1994 Feb; 102(2):258-9.
Score: 0.005
-
Sanchez A, Robinson WA, Cohn A, Gonzalez R, Adlakha A. Low-dose alpha-interferon treatment of chronic myeloid leukemia. Am J Hematol. 1992 Jan; 39(1):61-2.
Score: 0.005
-
Gordon GS, Ambruso DR, Robinson WA, Githens JH. Intranasal administration of deferoxamine to iron overloaded patients. Am J Med Sci. 1989 May; 297(5):280-4.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|